Tradjenta shows long term benefits for Type 2 Diabetes patients

Results of a two-year Phase III study of Tradjenta (linagliptin), from Boehringer and Eli Lilly, show significant reductions in blood glucose for adults with Type 2 Diabetes. Presented at the 47 th Annual Meeting of the European Association for the Study of Diabetes, the study revealed the efficacy and tolerability of Tradjenta as mono-, dual- (plus metformin or initial combination with pioglitazone) or triple (plus metformin and sulphonylurea) oral therapy. Reductions in HbA1c of 0.8% after 24 weeks of blinded treatment were seen to be durable over the additional 78 weeks. Overall, the rate of hypoglycaemic events was low and body weight remained unchanged. An additional 12-week study also indicated the efficacy and tolerability of linagliptin as add-on therapy to metformin. The data also demonstrates Tradjenta's safety and tolerability profile across the full spectrum of Type 2 Diabetes, from newly diagnosed patients to those with severe renal impairment.